CL2009000091A1 - Enzima n-acetilgalactosamina-6-sulfatasa (galns) humana recombinante; usos de la enzima galns contra mucopolisacaridosis tipo iv o sindrome de morquio a o deficiencias de multiples sulfatasas. - Google Patents

Enzima n-acetilgalactosamina-6-sulfatasa (galns) humana recombinante; usos de la enzima galns contra mucopolisacaridosis tipo iv o sindrome de morquio a o deficiencias de multiples sulfatasas.

Info

Publication number
CL2009000091A1
CL2009000091A1 CL2009000091A CL2009000091A CL2009000091A1 CL 2009000091 A1 CL2009000091 A1 CL 2009000091A1 CL 2009000091 A CL2009000091 A CL 2009000091A CL 2009000091 A CL2009000091 A CL 2009000091A CL 2009000091 A1 CL2009000091 A1 CL 2009000091A1
Authority
CL
Chile
Prior art keywords
enzyme
galns
sulfatase
acetylgalactosamine
recombinant human
Prior art date
Application number
CL2009000091A
Other languages
English (en)
Inventor
Erno Pungor
Michel Claude Vellard
Vish Koppaka
Melita Dvorak-Ewell
Charles Hague
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451345&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000091(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of CL2009000091A1 publication Critical patent/CL2009000091A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06014—N-Acetylglucosamine-6-sulfatase (3.1.6.14)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)

Abstract

UNA ENZIMA N-ACETILGALACTOSAMINA-6-SULFATASA (GALNS( HUMANA RECOMBINANTE DE UNA SECUENCIA DE AMINOACIDOS CON AL MENOS 95°'O DE IDENTIDAD RESPECTO A LOS AMINOACIDOS 27 A 522 DE SEQ ID NO: 4, DONDE DICHA ENZIMA GALNS: (A) TIENE AL MENOS UNA CONVERSIÓN DEL 50% DEL RESIDUO DE CISTEINA EN (A POSICIÓN 53 EN CN-FORMILGLICINA (FGIY); Y (B) ESTÁ GLICOSILADA CON ENLACE N EN LOS RESIDUOS DE ASPARAGINA EN LAS POSICIONES 178 Y 397, DONDE AL MENOS SO% DE LAS CADENAS DE OLIGOMANOSA ADHERIDAS AL RESIDUO ASPARAGINA EN LA POSICIÓN 178 SON BIS-FOSFORILADAS; DONDE DICHA ENZIMA CONSISTE DE UNA BANDA DE 55-60 KDA. USO DE DICHA ENZIMA PARA EL TRATAMIENTO DE MUCOPOLISACARIDOSIS TIPO IVA (MPS IVA) O SÍNDROME DE MORQUÍO A, O DEFICIENCIA DE MÚLTIPLES SULFATASAS (MSD).
CL2009000091A 2008-01-18 2009-01-16 Enzima n-acetilgalactosamina-6-sulfatasa (galns) humana recombinante; usos de la enzima galns contra mucopolisacaridosis tipo iv o sindrome de morquio a o deficiencias de multiples sulfatasas. CL2009000091A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2217908P 2008-01-18 2008-01-18
US9937308P 2008-09-23 2008-09-23
US11024608P 2008-10-31 2008-10-31

Publications (1)

Publication Number Publication Date
CL2009000091A1 true CL2009000091A1 (es) 2009-03-27

Family

ID=40451345

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000091A CL2009000091A1 (es) 2008-01-18 2009-01-16 Enzima n-acetilgalactosamina-6-sulfatasa (galns) humana recombinante; usos de la enzima galns contra mucopolisacaridosis tipo iv o sindrome de morquio a o deficiencias de multiples sulfatasas.

Country Status (29)

Country Link
US (7) US8128925B2 (es)
EP (3) EP4413994A3 (es)
JP (1) JP5687069B2 (es)
KR (1) KR101744142B1 (es)
CN (3) CN105274072A (es)
AR (1) AR070198A1 (es)
AU (1) AU2009205978B2 (es)
BR (1) BRPI0906948B1 (es)
CA (3) CA3295047A1 (es)
CL (1) CL2009000091A1 (es)
CY (2) CY1118984T1 (es)
DK (2) DK2245145T3 (es)
ES (1) ES2984846T3 (es)
FI (1) FI3219795T3 (es)
HR (2) HRP20170366T1 (es)
HU (3) HUE066911T2 (es)
IL (1) IL206975A (es)
LT (3) LT3219795T (es)
MX (1) MX2010007846A (es)
NL (1) NL300874I2 (es)
NO (1) NO2017024I1 (es)
PE (2) PE20140841A1 (es)
PL (2) PL3219795T3 (es)
PT (2) PT2245145T (es)
RU (1) RU2510820C2 (es)
SI (2) SI3219795T1 (es)
TW (1) TWI395816B (es)
WO (1) WO2009091994A2 (es)
ZA (1) ZA201004674B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008120107A2 (en) 2007-04-03 2008-10-09 Oxyrane (Uk) Limited Glycosylation of molecules
CN105274072A (zh) * 2008-01-18 2016-01-27 生物马林药物股份有限公司 制备活性高度磷酸化人溶酶体硫酸酯酶及其应用
US9598682B2 (en) 2009-09-29 2017-03-21 Vib Vzw Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose
US20130053550A1 (en) 2009-11-19 2013-02-28 Oxyrane Uk Limited Yeast strains producing mammalian-like complex n-glycans
RS62620B1 (sr) 2010-06-25 2021-12-31 Shire Human Genetic Therapies Metode i kompozicije za isporuku cns akrilsulfataze a
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
US9347050B2 (en) 2010-09-29 2016-05-24 Oxyrane Uk Limited Mannosidases capable of uncapping mannose-1-phospho-6-mannose linkages and demannosylating phosphorylated N-glycans and methods of facilitating mammalian cellular uptake of glycoproteins
WO2012042387A2 (en) 2010-09-29 2012-04-05 Oxyrane Uk Limited De-mannosylation of phosphorylated n-glycans
US20130236442A1 (en) * 2010-11-12 2013-09-12 Green Cross Corporation Iduronate-2-sulfatase and use thereof
AU2010366066B2 (en) * 2010-12-22 2016-01-14 Fondazione Telethon Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses
TW201307563A (zh) 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素－ｎ－硫酸酯酶之方法
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
EP3628326B1 (en) 2012-03-15 2024-02-28 Oxyrane UK Limited Methods and materials for treatment of pompe's disease
WO2013148323A1 (en) * 2012-03-30 2013-10-03 Shire Human Genetic Therapies Methods of analyzing and preparing protein compositions
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) * 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
CN104854122B (zh) * 2012-11-13 2021-10-08 意大利凯西制药公司 重组人半乳糖脑苷脂-β-半乳糖苷酶(rhGALC)的纯化
US20190040368A1 (en) * 2013-03-05 2019-02-07 Oxyrane Uk Limited Production of catalytically active type i sulfatase
CA2938498A1 (en) 2014-02-18 2015-08-27 Shire Human Genetic Therapies, Inc. Substrate clearance assays for lysosomal enzymes
HUE039691T2 (hu) * 2014-04-01 2019-01-28 Swedish Orphan Biovitrum Ab Publ Módosított szulfamidáz és elõállítása
EP3101125A1 (en) * 2015-06-05 2016-12-07 Laboratorios Del Dr. Esteve, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
AU2016349528A1 (en) 2015-11-06 2018-05-17 Biomarin Pharmaceutical Inc. Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes
RU2673038C2 (ru) * 2016-01-18 2018-11-21 ООО "Международный Биотехнологический Центр "Генериум" Лекарственное средство на основе бифункционального антитела для лечения мукополисахаридоза II типа
JP6430980B2 (ja) * 2016-03-09 2018-11-28 フォンダッツィオーネ・テレソン ムコ多糖症におけるｃｎｓ病変を処置するための治療戦略
US11584777B2 (en) 2017-08-31 2023-02-21 Green Cross Corporation Method for purifying a sulfatase protein
AU2018345303B2 (en) 2017-10-02 2025-09-18 Denali Therapeutics Inc. Fusion proteins comprising enzyme replacement therapy enzymes
EP3963073A4 (en) * 2019-04-29 2023-01-25 The University of North Carolina at Chapel Hill OPTIMIZED SUMF1 GENES AND EXPRESSION CASSETTE AND THEIR USE
RU2763990C2 (ru) * 2020-02-19 2022-01-12 Акционерное общество "ГЕНЕРИУМ" Клетка, продуцирующая с высокой эффективностью активный белок арилсульфатазу в, и способ получения этой клетки
PE20231931A1 (es) 2020-10-14 2023-12-01 Denali Therapeutics Inc Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas
US20240350653A1 (en) * 2021-08-18 2024-10-24 Joint-Stock Company "Generium" Targeted delivery of therapeutic enzymes

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US5186941A (en) 1983-05-06 1993-02-16 Vestar, Inc. Vesicle formulation for the controlled release of therapeutic agents
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
NZ245015A (en) 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
TW492882B (en) 1997-11-28 2002-07-01 Caleb Pharmaceuticals Inc Cholinergic antagonist plaster composition
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US6972124B2 (en) 2000-05-01 2005-12-06 Biomarin Pharmaceuticals Inc. Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
DK1395669T3 (da) 2001-01-26 2009-11-16 Selexis Sa Matriks bindingsregioner og fremgangsmåder til anvendelse af disse
US20030040095A1 (en) * 2001-03-16 2003-02-27 Achille Arini Method for the production of pharmaceutically active recombinant proteins
AUPS293002A0 (en) 2002-06-14 2002-07-04 Women's And Children's Hospital Identification of oligosaccharides and their use in the diagnosis and evaluation of mucopolysaccharidoses and other related disorders
EP2325301B1 (en) 2003-02-11 2015-09-02 Shire Human Genetic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and others using a formylglycine generating enzyme (FGE)
US8536315B2 (en) * 2004-01-30 2013-09-17 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulftase
CA2556245A1 (en) * 2004-02-06 2005-08-25 Biomarin Pharmaceutical Inc. Manufacture of highly phosphorylated lysosomal enzymes and uses thereof
WO2005113765A2 (en) * 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
US7863238B2 (en) 2004-06-10 2011-01-04 Saint Louis University Proteins with an attached short peptide of acidic amino acids
EP2177614B1 (en) 2005-05-02 2014-12-31 Toray Industries, Inc. Composition and method for diagnosing esophageal cancer and metastasis of esophageal cancer
EP1818395A1 (en) * 2006-02-08 2007-08-15 Diatos Compositions and methods for treating lysosomal storage diseases
CA2674493C (en) 2007-01-05 2017-05-09 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
WO2009034159A1 (en) 2007-09-12 2009-03-19 Vivendy Therapeutics Ltd: Short polypeptide mediated conformational changes promoting enhancement of enzymatic activity
US7722865B2 (en) * 2008-01-18 2010-05-25 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
CN105274072A (zh) 2008-01-18 2016-01-27 生物马林药物股份有限公司 制备活性高度磷酸化人溶酶体硫酸酯酶及其应用
AR082319A1 (es) * 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos

Also Published As

Publication number Publication date
CN121109347A (zh) 2025-12-12
US20200181590A1 (en) 2020-06-11
KR101744142B1 (ko) 2017-06-07
US20120208221A1 (en) 2012-08-16
HK1244505A1 (en) 2018-08-10
LTC2245145I2 (lt) 2019-04-25
HRP20240732T3 (hr) 2024-08-30
SI2245145T1 (sl) 2017-05-31
DK3219795T3 (da) 2024-06-17
AU2009205978B2 (en) 2014-04-10
DK2245145T3 (en) 2017-03-20
PL2245145T3 (pl) 2017-07-31
US8128925B2 (en) 2012-03-06
ES2984846T3 (es) 2024-10-31
US8420368B2 (en) 2013-04-16
RU2010134412A (ru) 2012-02-27
IL206975A0 (en) 2010-12-30
CA3112632A1 (en) 2009-07-23
CN105274072A (zh) 2016-01-27
US20160201039A1 (en) 2016-07-14
TW200934869A (en) 2009-08-16
EP3219795A1 (en) 2017-09-20
EP4413994A3 (en) 2024-12-18
WO2009091994A2 (en) 2009-07-23
US9200264B2 (en) 2015-12-01
US20180208913A1 (en) 2018-07-26
EP4413994A2 (en) 2024-08-14
FI3219795T3 (fi) 2024-06-12
BRPI0906948B1 (pt) 2023-05-16
KR20100108438A (ko) 2010-10-06
EP2245145A2 (en) 2010-11-03
AR070198A1 (es) 2010-03-17
HRP20170366T1 (hr) 2017-05-05
PT2245145T (pt) 2017-03-14
US10934534B2 (en) 2021-03-02
ZA201004674B (en) 2011-09-28
WO2009091994A3 (en) 2009-10-29
HUE032074T2 (en) 2017-08-28
US10563183B2 (en) 2020-02-18
BRPI0906948A2 (pt) 2015-07-14
US20130236921A1 (en) 2013-09-12
JP5687069B2 (ja) 2015-03-18
JP2011509674A (ja) 2011-03-31
CA2711590C (en) 2021-03-23
PT3219795T (pt) 2024-06-18
TWI395816B (zh) 2013-05-11
HUE066911T2 (hu) 2024-09-28
PE20140841A1 (es) 2014-08-03
US9873867B2 (en) 2018-01-23
EP3219795B1 (en) 2024-03-13
PE20091319A1 (es) 2009-09-23
HUS1700022I1 (hu) 2017-06-28
CY2017018I1 (el) 2017-11-14
CA3295047A1 (en) 2026-03-02
WO2009091994A9 (en) 2009-12-03
MX2010007846A (es) 2010-10-05
SI3219795T1 (sl) 2024-10-30
IL206975A (en) 2013-06-27
NO2017024I1 (no) 2017-05-30
NL300874I2 (nl) 2018-04-12
LT3219795T (lt) 2024-07-25
US20090186011A1 (en) 2009-07-23
CA2711590A1 (en) 2009-07-23
US20210189357A1 (en) 2021-06-24
CN102027110A (zh) 2011-04-20
PL3219795T3 (pl) 2024-09-16
US12188058B2 (en) 2025-01-07
LTPA2017016I1 (lt) 2017-06-12
LT2245145T (lt) 2017-04-10
AU2009205978A1 (en) 2009-07-23
EP2245145B1 (en) 2016-12-14
CY2017018I2 (el) 2017-11-14
RU2510820C2 (ru) 2014-04-10
CY1118984T1 (el) 2017-11-14

Similar Documents

Publication Publication Date Title
CL2009000091A1 (es) Enzima n-acetilgalactosamina-6-sulfatasa (galns) humana recombinante; usos de la enzima galns contra mucopolisacaridosis tipo iv o sindrome de morquio a o deficiencias de multiples sulfatasas.
AR119552A2 (es) Producción de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
ES2532985T3 (es) Proteínas quiméricas de toxoide de Shiga
UY33222A (es) Secuencias de aminoácidos dirigidas contra el receptor de superficie celular 2 de TRAIL, compuestos, construcciones y variantes efectivas
CO6430475A2 (es) Polipéptidos que tienen actividad de celulasa
BR112012033404A2 (pt) polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos.
ES2571757T3 (es) Microorganismos con rango de utilización de sustrato ampliado
AR081200A1 (es) Formulaciones de insulina de accion prolongada
EA201170879A1 (ru) Полипептиды с ксиланазной активностью
AR074311A1 (es) Variantes de subtilisina aislada de bacillus, con actividad proteolitica
PE20160507A1 (es) Diferenciacion de celulas madre mesenquimales
ES2627117T3 (es) Método basado en MGMT para obtener un rendimiento elevado de expresión de proteínas recombinantes
DE602006018969D1 (de) Herstellung und reinigung von il-29
ES2694667T3 (es) Método para producir oxalato oxidasas que tienen actividad óptica cerca de pH fisiológico y uso de tales oxalato oxidasas recombinantes en el tratamiento de enfermedades relacionadas con oxalato
MX2021008131A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
AR060471A1 (es) Organismos clostridium recombinantes atenuados y vacuna
MX366906B (es) Purificacion de iduronato-2-sulfatasa.
AR066410A1 (es) Nuevas asparraginasas y sus usos
BR112013003522A8 (pt) "polipeptídeos relaxina modificados compreendendo um aminoácido não codificado naturalmente, uso, método de preparação, bem como ácido nucleico codificando os mesmos"
SG178797A1 (en) Oligosaccharide chain added glp-1 peptide
NZ715014A (en) Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients
AR060827A1 (es) Metodo para bloquear la infeccion por flavivirus, moleculas y usos
AR100606A1 (es) Variantes de lipasas y polinucleótidos que las codifican
CY1117335T1 (el) Εμβολιο pcsk9
CO6470864A2 (es) Combinaciones de clados de rrgb neumococicos